PCSK9 Forum
8th December 2015
Facebook Twitter RSS YouTube
For latest updates
Register today
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact
Hot Off the Press
PCSK9 Inhibitors and Cardiovascular Disease
Heralding a New Therapeutic Era

PCSK9 Forum Editors review the latest PCSK9 developments.

The first PCSK9 monoclonal antibody treatments were approved in Europe and the US earlier this year. Here, the Editors make the case for their use in severe familial hypercholesterolaemia (FH, inherited high cholesterol). Other high risk patients, including those who cannot tolerate statins, are also a priority.

Read the latest in the PCSK9 story here » Forward to colleagues »

Legacy Effects from PCSK9 Inhibitor Treatment?

Does profound LDL lowering with PCSK9 inhibition offer the possibility to alter the natural history of atherosclerotic vascular disease?
Professor Chris Packard poses the questions.

Read the editorial here »
  Chris Packard

In the News

Looking Back at AHA 2015
Roving PCSK9 Forum News Reporter Dr Peter Lansberg gives his views on the highlights.

Read the full report »
Scientific Sessions 2015 Dr Peter Lansberg

Other News
Free e-book
Understanding PCSK9 inhibition
For healthcare professionals

Prepared by independent experts from PCSK9 Education and Research Forum.

Available free to registered members of the Forum.

Register and read online »    Download now »
PCSK9 Inhibition Handbook

Like us on Facebook
For the latest updates on conferences, PCSK9 news and video reports.
Follow us on Twitter
For updates on hot topics,
PCSK9 news and conference reports.
YouTube Channel
For the latest videos, interviews and webcasts from leading experts.
Educational Partners
and Supporters
Amgen Lilly The Medicines Company pFizer Sanofi
Copyright PCSK9 Forum 2015. Please click here to unsubscribe from future mailings.